Issue Date: February 14, 2011
Merck Gives Back Galapagos Programs
Merck & Co. has ended its obesity, diabetes, and atherosclerosis drug discovery collaboration with Galapagos. The Belgian biotech firm will receive $16 million for work completed in 2010, bringing total payments from Merck in the past two years to roughly $28 million. Galapagos regains the rights to all targets discovered and assays developed by the alliance, which began in early 2009 as a metabolic diseases collaboration and was later expanded to include atherosclerosis. Merck says it is ending the pact as a result of changes in its early discovery strategy.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society